Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | PPM1B | O75688 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.38 |
| ▸ | ARG1 | P05089 | 3/20 | 0.38 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10430282 | 1.00 | SLC1A2 (0.64) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| SCHEMBL28060858 | 0.89 | MEN1 (0.67) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| SCHEMBL10515839 | 0.88 | SLC1A2 (0.47) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| SCHEMBL26134530 | 0.88 | SLC1A2 (0.47) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL31228335 | 0.87 | MEN1 (0.65) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL31228685 | 0.87 | MEN1 (0.65) | SLC1A2MEN1BLMKMT2ACHRM2 | |
| SCHEMBL24023349 | 0.80 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2APPM1B | |
| SCHEMBL3427826 | 0.80 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL17756064 | 0.80 | SLC1A2 (0.58) | SLC1A2MEN1BLMKMT2AARG1 | |
| SCHEMBL2177045 | 0.79 | SLC1A2 (1.00) | SLC1A2MEN1BLMKMT2AARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | SLC1A2 3492/4885MEN1 150/4885BLM 1425/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SLC1A2 3492/4885MEN1 150/4885BLM 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.